Sugi Predict
/ Targets
/ FANCF
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
![Rutin]() |
Rutin (SCHEMBL23243) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL23244) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL148590) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL796642) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL802819) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL2017898) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL5580506) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL5580508) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL5918715) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL6552718) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL8193625) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL10285592) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL13696392) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL13696608) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL14369486) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL14952130) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL15025698) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL15029221) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL15263233) |
1.00 |
2/20 |
![Rutin]() |
Rutin (SCHEMBL15591879) |
1.00 |
2/20 |
Clinical trials — most relevant to FANCF by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Eltrombopag for People With Fanconi Anemia |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors |
PHASE2 | COMPLETED |
| Prenatal Transplantation for Fetuses With Fanconi Anemia |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Gene Therapy for Fanconi Anemia, Complementation Group A |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100 |
PHASE1/PHASE2 | COMPLETED |
| M6620 (VX-970) in Selected Solid Tumors |
PHASE2 | COMPLETED |
| Efficacy and Safety of PARPi to Treat Pancreatic Cancer |
PHASE2 | COMPLETED |
| HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy |
PHASE2 | RECRUITING |
| A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Olaparib in Treating Patients With Stage IV Pancreatic Cancer |
PHASE2 | COMPLETED |
| Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission |
PHASE1/PHASE2 | COMPLETED |
| A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors |
PHASE1 | COMPLETED |
| Gene Therapy for the Treatment of Fanconi's Anemia Type C |
PHASE1 | COMPLETED |
| Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors |
PHASE1 | COMPLETED |
| Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia |
PHASE1 | COMPLETED |
| Quercetin in Children With Fanconi Anemia; a Pilot Study |
PHASE1 | COMPLETED |
| Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia |
EARLY_PHASE1 | COMPLETED |
| Corrective Exercise and Rehabilitation in Fanconi Anemia: A Case Study |
nan | COMPLETED |
| Clinical Genetics Branch Eligibility Screening Survey |
nan | NOT_YET_RECRUITING |
| Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma |
nan | COMPLETED |
| Utility of a Urine Screening Tool for Vitamin D Deficiency in Infants and Toddlers |
nan | COMPLETED |
| Cancer in Inherited Bone Marrow Failure Syndromes |
nan | RECRUITING |
| Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy |
nan | ACTIVE_NOT_RECRUITING |
| Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base |
nan | RECRUITING |
| Men at High Genetic Risk for Prostate Cancer |
nan | RECRUITING |
| Prognostic Significance of Mutation Type and Chromosome Fragility in Fanconi Anemia |
nan | COMPLETED |
| Stereo Photogrammetry Imaging in Normal Volunteers and Patients With Head and Facial Malformations |
nan | COMPLETED |
| Microcephaly Genetic Deficiency in Neural Progenitors |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a FANCF binder may also engage these)